L3VLUP
ProSign in

PRCT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PRCTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PRCT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterPRCTLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20214 holders, $191m31 holders, $29.9bn
Q4 20213 holders, $124m31 holders, $34.7bn
Q1 20222 holders, $128m24 holders, $35.3bn
Q2 20222 holders, $51m33 holders, $42.7bn
Q3 20221 holders, $16k31 holders, $43.4bn
Q4 20222 holders, $768k31 holders, $46.6bn
Q1 20233 holders, $11m33 holders, $44.3bn
Q2 20231 holders, $1.8m37 holders, $59.6bn
Q3 20231 holders, $1.4m44 holders, $67.6bn
Q4 20233 holders, $103m45 holders, $73.6bn
Q1 20245 holders, $129m41 holders, $95.3bn
Q2 20246 holders, $610m43 holders, $110bn
Q3 20245 holders, $768m45 holders, $107bn
Q4 20249 holders, $1.0bn46 holders, $93.9bn
Q1 20256 holders, $718m42 holders, $98.4bn
Q2 20253 holders, $232m43 holders, $93.2bn
Q3 20253 holders, $201m39 holders, $86.7bn
Q4 20254 holders, $194m41 holders, $123bn
Q1 20263 holders, $56m39 holders, $106bn
Q2 20262 holders, $36m44 holders, $132bn
PRCT

Procept Biorobotics Corp

Holders
5
Reported value
$768m
Buyers
1
Sellers
4

Breadth -3 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PRCT (0)

None.

Only LLY (40)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, and 15 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →